Social Media Ideas for Inside Labiotech

Inside one of Europe’s most advanced biotech innovation hubs

Discover M600 in Marburg: a 40,000 m² biotech campus bringing research, pilot-plant, and GMP together in one European innovation ecosystem. The post Inside one of Europe’s most ad...

We asked, you answered: Labiotech’s 2026 reader survey results

Labiotech's reader survey reveals what our audience wants, needs, and is interested in for 2026. The post We asked, you answered: Labiotech’s 2026 reader survey results appeared fi...

Munich’s biotech hub: Inside one of Europe’s leading life sciences ecosystems

Discover the factors driving the success of Munich's biotech hub, which is now one of the leading clusters in Europe. The post Munich’s biotech hub: Inside one of Europe’s leading...

Could your microbial process be stronger? Uncovering opportunities before scale-up and commercialization

Discover how small adjustments make your microbial process more robust and reproducible during scale-up and technology transfer. The post Could your microbial process be stronger?...

Life science industry in Geneva on a roll 

Geneva’s life science industry is bound to western Switzerland's Health Valley ecosystem but is also growing in and of itself. The post Life science industry in Geneva on a roll ...

Streamlining stable cell line development from the start

Discover how early optimization in stable cell line development accelerates timelines and reduces downstream bottlenecks. The post Streamlining stable cell line development from th...

Top biotech deals in August 2026 

Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and metabolic disease. The post Top biotech deals in August 2026...

Eight biotech companies in Melbourne you should know about 

Discover 8 biotech companies in Melbourne, ranging from commercial to preclinical-stage companies, advancing promising technologies. The post Eight biotech companies in Melbourne...

Roche’s new gene sequencer on the market: where do current players stand? 

Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance? The post Roche’s new gene sequencer on the market: where...

Eight biotechnology companies leading the charge in Poland

Discover eight biotech companies at the forefront of Poland’s emerging biotech sector, which is becoming a hotspot for startups. The post Eight biotechnology companies leading the...

Bioz and InvivoGen Elevate Scientific Discovery with an Expanded Digital Research Experience

Genomes to bioreactors: Saudi Arabia’s gene editing oncology push

Saudi Arabia is pairing gene editing breakthroughs with new biomanufacturing capacity, from CRISPR oncology therapies to CDMOs like Lifera, as it builds a full biotech pipeline. Th...

How BIO-Europe is expanding beyond dealmaking in 2026

BIO-Europe has always been the destination for BD professionals and dealmakers. In 2026, it's broadening its scope to become what the organizers are calling the epicenter of biotec...

Elevating Modern Research Standards: How Next-Generation Synthesis and Testing Protocols Are Reshaping Laboratory Suppli...

With backing from Sam Sulek, NewBioRx sets new benchmarks in research-grade purity through advanced HPLC/MS validation and stringent quality control. In the fast-evolving landscape...

Top biotech deals in July 2026 

The top biotech deals of July 2026 were over small molecules, cell therapies, antibodies, RNA therapeutics, vaccines, and AI. The post Top biotech deals in July 2026  appeared fir...

BIOSPAIN 2026: partnering, policy, and the rise of Spanish biotech

Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026. The post BIOSPAIN 2026: partnering, policy, and the ri...

Investor confidence is built beyond the data

See why investor confidence in cell and gene therapies now depends on execution and supply chain strategy—not strong science alone. The post Investor confidence is built beyond the...

Six MASH biotech companies shaping the future of liver disease treatment

Discover six MASH companies to keep an eye on as the race to shape the next generation of liver disease therapies heats up. The post Six MASH biotech companies shaping the future o...

Seven companies leading the mRNA revolution in biotechnology

Here are seven mRNA biotechs that have raised funds in recent years to push their candidates ahead through preclinical and clinical trials. The post Seven companies leading the mRN...

The biggest biotech funding rounds in August 2026

The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August 2026. The post The biggest biotech funding rounds in A...

End-to-end: Curia drives supply and scale for steroid and hormonal therapies

Explore how Curia tackles steroid manufacturing complexity, from early development to scaled, end-to-end commercial supply. The post End-to-end: Curia drives supply and scale for s...

Biotech hub near Athens has lofty goals

Not far from Athens’ airport, a biotechnology hub has sprung up this year. The Athens LifeTech Park (ALTP) has been formed to support the full cycle of scientific innovation, from...

BIO-Europe 2026: Expanding the scope at Europe’s leading biotech partnering event

BIO-Europe 2026 heads to Cologne this November, expanding from three tracks to seven to reach the full biotech and pharma C-suite. The post BIO-Europe 2026: Expanding the scope at...

The biggest biotech funding rounds in July 2026

The companies BridgeBio, Erasca, Chai Discovery, and MeiraGTx bagged the biggest biotech funding rounds overall in July 2026. The post The biggest biotech funding rounds in July 20...